RxDoctor Payments Data

Heather Hermoso

Family · Abilene, TXNPI 1235776055

Payments from drug & device makers

$4,393in general payments, 2019–2025

Across 225 payments — averaging $19.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Livanova USA, Inc.$481
  • Pfizer$406
  • Biogen$386
  • Biohaven Pharmaceuticals, Inc.$278
  • UCB, Inc.$240
  • plus $2K from 22 others

What the payments were for

  • Travel & lodging$2355%
  • Food & beverage$4,15995%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,393 in reported general payments places this provider in the 90th percentile of 15,456 family providers in Texas.

See all family providers in Texas

Medicare billing

Part B allowed, 2024
$90,500
Medicare patients
289
Services billed
4,432

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Kesimpta PenOfatumumab16$218,328
Nurtec OdtRimegepant Sulfate63$97,079
UbrelvyUbrogepant66$92,516
Aimovig AutoinjectorErenumab-Aooe54$58,180
QuliptaAtogepant41$54,493
GocovriAmantadine Hcl14$45,629
BotoxOnabotulinumtoxina33$39,779
Emgality PenGalcanezumab-Gnlm20$30,395
Lamictal XrLamotrigine21$26,745
Levetiracetam334$16,941
AptiomEslicarbazepine Acetate12$16,423
Oxcarbazepine80$10,566
Divalproex Sodium ErDivalproex Sodium77$7,338
Lacosamide61$7,124
Carbamazepine79$6,902

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieUbrelvy, Qulipta, Botox$1,003$186,789140 claims
PfizerNurtec Odt$406$97,07963 claims
Upsher-smith Laboratories LLCTopiramate$45$3,654281 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 15,456 family providers in Texas.

Other family in Abilene

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →